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Diagnosis of heart failure (HF) is not based on a single test, but on a combination of history, physical examination
and appropriate investigations. For these reasons, the accuracy of diagnosis by clinical means alone is often inad-
equate, especially in the early, asymptomatic stages of the HF. Thus, there is an increasing interest in the devel-
opment of new cardiovascular biomarkers and, consequently, a great number of laboratory tests have recently
been proposed for their assay. The aim of this article is to provide a general overview on the biomarkers, recom-
mended by international guidelines, for the diagnosis, risk stratiﬁcation, and follow-up of patients with HF. Car-
diac natriuretic peptides and in particular the B-type related peptides, which are considered to be the ﬁrst line
biomarker for HF by international guidelines, will be discussed with special emphasis.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
Estimates on the prevalence of symptomatic heart failure (HF) in
the general European and North American population range from
0.4% to 2% [1–5]; with age, HF incidence and prevalence increase
steeply, approaching 1 in 1000 among people over the age of 65
[1–5]. From an economic point of view, compared to other diagnoses
and treatments, HF is the primary expenditure in Medicare in the US
[4], and in healthcare setting across European countries [1–3].
Despite the remarkable advances made during the past 50 years in
understanding and treating the disease [6,7], HF continues to have a
poor prognosis: approximately up to 40% of patients diagnosedwith se-
vere heart failure (NYHA class III–IV or ACC/AHA stage D) in the
European and North American population die within one year, with
survival rates similar to those of colon cancer, and worse than those of
breast or prostate cancer [1–5].
About 20 years ago, Braunwald and Bristow [8] suggested the in-
triguing hypothesis that it may be possible to reverse the process of
HF, which had long been considered to be irreversible and amenable
only to palliative therapy. According to this hypothesis, the intrinsic de-
fects in myocardial contraction featured by some patients with chronic
HF could be partially reversed by connecting the patient to a ventricular
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assist device for several months [9] and/or using an appropriate
pharmacological treatment [8]. In particular, it is now well docu-
mented that patients with chronic HF, treated with β-adrenergic
blocking agents, added to background therapy with ACE inhibitors,
improve the systolic function and may reverse cardiac remodeling,
leading a better clinical outcomes, including prolonged survival and
reduced hospitalizations [1–5]. Thus, the view of chronic HF as an irre-
versible, end-stage process is being replaced by the concept that intrin-
sic defects of function and structure afﬂicting the chronically failing
heart can be addressed through appropriate therapy [6]. From a theo-
retical point of view, we can indeed assume that it is easier to arrest –
or even reverse – a progressive process such as HF if action is taken in
the earliest phase of the cardiac alteration.
In order to emphasize both the development and progression of the
disease, the ACC/AHA guidelines for the diagnosis and management of
chronic HF in the adult recommend a classiﬁcation of HF based on 4
stages from A to D (Fig. 1) [4]. The ﬁrst two stages (A and B) do not in-
clude symptomatic patients in an attempt to underscore to healthcare
providers the importance of an early identiﬁcation of patients who are
at risk for developing HF. In particular, patients in stage A have only
risk factors without structural or functional alterations of ventricular
myocardial, while those in stage B show cardiac structural (such as
hypertrophy) and/or functional (such as impaired left ventricular
dysfunction) alterations. The last two stages C and D identify instead
symptomatic patients. Since early identiﬁcation of individuals and risk
stratiﬁcation anddiagnosis can be achieved today through themeasure-
ment of speciﬁc disease or risk markers, an increasing number of new
cardiovascular biomarkers have been proposed, as previously reviewed
in detail [9–17].
The aim of this review article is to provide a general outline on the
methodology of the biomarkers recommended by international guide-
lines for the diagnosis, risk stratiﬁcation, and follow-up of patients
with HF, with special emphasis on natriuretic peptides, which are
considered to be the most useful biomarker for HF.
2. The clinical relevance of biochemical biomarkers in heart failure
HF is deﬁned as a syndrome, resulting from any structural or func-
tional cardiac disorder that impairs the ability of the heart to function
as a pump to support a physiological circulation [1–5]. The diagnosis
of HF is not based on one single test [1,2]. Positive history and some
physical signs (such as orthopnea, rales, third heart sound or jugular
vein distension) share a good diagnostic speciﬁcity, but also a poor
sensitivity in diagnosing acute congestive HF (Table 1) [16,17]. There-
fore, the diagnosis of both acute and chronic HF relies on clinical judg-
ment based on a combination of history, physical examination and
Fig. 1. Schematic representation of biosynthesis, secretion and distribution of B-type related natriuretic peptides. Human BNP is synthesized as a 134-amino acid (aa) precursor protein
(pre-proBNP), including a signal peptide of 26 amino acids (grey), and is subsequently processed to form a 108-aa pro-peptide, named proBNP. The proBNP can be enzymatically cleaved
by pro-protein convertases produced in the cardiomyocytes, such as corin and furin,mainly located in the trans-Golgi network and on the plasmamembrane, respectively [116]. ProBNP is
thus processed to form the 76-aa N-terminal peptide (NT-proBNP, violet) and the biologically active 32-aa C-terminal peptide (BNP, light blue), which are both secreted into plasma. Some
of the proBNP is O-glycosylated within the Golgi apparatus. Proteolytic cleavage occurs either on or not O-glycosylated proBNP. But, if O-glycans bind to the threonine at position 71 the
proBNP will not be processed by furin and corin, thus glycosylated proBNP will be secreted into circulation. Finally, also not glycosylated proBNP can be released as unprocessed peptide.
However, the latter can be cleaved intoNT-proBNP and BNPbyplasmatic corin [117–120]. Only BNP1–32, which is the active hormone, is able to bind the speciﬁc receptors, NPR-A andNPR-
C. NPR-A is a guanylate cyclase-coupled receptor, whichmediates the biological effects of cardiac natriuretic peptides. NPR-C, not coupled to a guanylate cyclase, has essentially a clearance
function for all natriuretic peptides.
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appropriate investigations, as recommended by all international guide-
lines [1–5,18,19].
According to the most recent international guidelines [18,19], na-
triuretic peptides, and in particular the peptides related to the B-type
cardiac peptide hormone (such as BNP and NT-proBNP), are recom-
mended as the ﬁrst line biomarker for the diagnosis of both acute
and chronic HF. The measurement of BNP and NT-proBNP is useful
in supporting clinical judgment for the diagnosis or exclusion of HF
in the setting of chronic ambulatory HF or acute decompensated HF
(with the maximum degree of class of recommendation I and level
of evidence A) [19]. The value of natriuretic peptide testing is partic-
ularly signiﬁcant when the etiology of dyspnea is unclear. Indeed, all
international guidelines, starting from the ﬁrst years of this century,
state that lower values of BNP or NT-proBNP actually exclude the
presence of HF and higher values have reasonably high positive pre-
dictive value to diagnose HF [1–4,18,19].
From a pathophysiological point of view, it is important to underline
that the cardiac endocrine function is an essential component of the
integrated systems of the body and, thus, plays a pivotal role in ﬂuid,
electrolyte and hemodynamic homeostasis [20,21]. A continuous and
intense information exchange ﬂows from the endocrine heart system to
nervous and immunological systems and to other organs, including the
kidney, endocrine glands, liver, adipose tissue, immunocompetent cells,
and vice versa. This close link between cardiac natriuretic peptide sys-
tem and counter-regulatory systems could explain the increase in circu-
lating levels of BNP/NT-proBNP in some noncardiac-related clinical
conditions [20,21] (Table 2).
As far as the follow-up of HF patients is concerned, BNP and NT-
proBNP levels mirror the effectiveness of the treatment of acute or
chronic HF, with lowering of levels over time associated with better
clinical outcomes [22,23]. Even if most trials examining the strategy of
biomarker “guided” HF management were small and underpowered,
at present time, 3 comprehensive meta-analyses concluded that BNP-
guided therapy reduces all-causemortality and cardiovascular hospital-
ization in patients with HF compared with usual clinical care, especially
in patients b75 years of age with co-morbidities [19,21,22,24–27].
As far as the stratiﬁcation of cardiovascular risk in HF patients is
concerned, measurement of natriuretic peptides is recommended
by the most recent guidelines with the maximum degree of evidence
(class I and level A) also for the prognosis in HF patient [19]. Several
studies have demonstrated that increased circulating levels of cardiac
troponin I (cTnI) and T (cTnT) – especially using high-sensitivity
methods [28,29] – are found in patients with HF, who often do not
present obviousmyocardial ischemia or underlying coronary artery dis-
ease [30–39]. These ﬁndings [30–39] suggest that increased cTnI and
cTnT in these patients could be caused by cardiomyocyte injury or ne-
crosis. In chronic or acute decompensatedHF, elevated cardiac troponin
levels are associated with worse clinical outcomes and mortality. In-
deed,HF patients, showing a signiﬁcant and lasting decrease in troponin
levels after appropriate pharmacological treatment have a better prog-
nosis compared to those did not show any or only transient decrease
[31,38]. Based on these results [30–39], the latest guidelines recom-
mend that troponin I or T be routinely measured, in addition to natri-
uretic peptides, in patients presenting with acutely decompensated
HF for evaluating risk stratiﬁcation, with the maximum degree of evi-
dence (class I and level A) [19].
In addition to natriuretic peptides and troponins, a huge number
of other biomarkers have been suggested for the prognostic value in
HF; for example, those related to pro-inﬂammatory mechanisms, ox-
idative stress, cachexia, neuro-hormonal dysfunction, and myocardial
remodeling, as previously reviewed in detail [9–17]. As an example, a
list of some of these suggested biochemical biomarkers is reported in
Table 3. In particular, several studies have suggested that biomarkers
of myocardial ﬁbrosis, such as galectin-3 [40–53] and soluble ST2
[54–64], are predictive of hospitalization and death in patients with
HF. Accordingly [40–64], the most recent guidelines [19] also suggest
the use of biomarkers of myocardial ﬁbrosis for additive risk stratiﬁca-
tion, although with a lower degree of evidence compared to natriuretic
peptides and troponins, in both ambulatory (class IIb, level B) and
acute (class IIb, level A) HF patients. In Table 4, we summarized
Table 1
Accuracy of history and physical ﬁndings in diagnosing acute congestive HF (modiﬁed
from references [16,17]).
Variable Sensitivity Speciﬁcity Accuracy
History of HF 62 94 80
Dyspnea 56 53 54
Orthopnea 47 88 72
Rales 56 80 70
Third heart sound 20 90 66
Jugular vein distension 39 94 72
Edema 67 68 68
Table 2
Selected causes of elevated natriuretic peptide concentrations (according to references
[19–21]).
Cardiac
• Heart failure, including right ventricular syndromes
• Acute coronary syndrome
• Heart muscle disease, including LVH
• Valvular heart disease
• Pericardial disease
• Atrial ﬁbrillation
• Myocarditis
• Cardiac surgery
• Cardioversion
Noncardiac
• Advancing age
• Anemia
• Renal failure
• Liver disease
• Pulmonary: obstructive sleep apnea, severe pneumonia, pulmonary hypertension
• Endocrine diseases (such as hyperthyroidism and primitive or secondary
hyperaldosteronism)
• Chronic inﬂammatory diseases (such as amyloidosis)
• Critical illness
• Bacterial sepsis
• Severe burns
• Toxic-metabolic insults, including cancer chemotherapy and envenomation
Table 3
Suggested prognostic biomarkers for HF.
Neuro-hormones
Natriuretic peptides (ANP, BNP, CNP and related peptides)
Thyroid hormones
Renin–angiotensin–aldosterone system
Catecholamines
Endothelins
Adrenomedullin
Urocortin
Leptin
Adiponectin
Cardiac damage biomarkers
Cardiac troponins, cTnI and cTnT
Remodeling and inﬂammatory biomarkers
Matrix metalloproteinases (MMPs)
Adhesion molecules (ICAM, VICAM, selectin-P)
C-Reactive Protein (CRP)
Cytokines and related receptor family (IL-2, IL-6, IL-8, TNF-α, ST2)
Pentraxin 3
Galectin 3
Oxidative stress molecular biomarkers
Gamma-glumatyltransferases (GGT)
Reactive oxygen species (ROS), Plasma oxidized LDL
Cachexia biomarkers
Alterations of hypophyseal–suprarenal axis
IGF-1 and GH
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some pathophysiological and methodological characteristics of bio-
markers, which are currently available and recommended by the most
recent international guidelines for HF according to evidence based
medicine principles [19].
3. The multi-markers (MM) approach to cardiovascular
risk evaluation
Based on the knowledge acquired so far, it is likely that HF thera-
py in the future will rely on strategies that combine multiple bio-
markers [9,13,16]. This methodological known as the multi-marker
(MM) approach or global risk model, is today considered the best
model for risk prediction in the individual patient with cardiovascu-
lar disease [13,65–67]. Unfortunately, the setup of an adequate MM
model is currently complicated by some theoretical and methodo-
logical difﬁculties [68]. According to the MM approach, each bio-
marker should contribute independently to the diagnostic and
prognostic accuracy in a multiple regression model, and ultimately
lead to a better outcome for the patient.
In 2010, an expert panel from the American Heart Association
established the criteria for the evaluation of novel markers of cardio-
vascular risk [69]. The panel stated that an adequate evaluation of a
novel risk marker should require (i) a sound research design, (ii) a
representative at-risk population, and (iii) an adequate number of
outcome events. Studies of a novel marker should report the degree
to which it adds to the prognostic information provided by standard
risk markers. Because no single statistical measure can provide all
the information needed to assess a novel marker, studies should
also report on measures of both discrimination and accuracy. Fur-
thermore, the clinical value of a marker should be assessed by its ef-
fect on patient management and outcomes.
In general, a novel riskmarker should be evaluated in several phases
according to Evidence-Based Laboratory Medicine principles [70],
including initial proof of concept, prospective validation in indepen-
dent populations, documentation of incremental information when
added to standard risk markers, assessment of effects on patient
management and outcomes, and ultimately, cost-effectiveness. Bio-
markers that do not change the management of a disease are proba-
bly unable to signiﬁcantly affect patient outcome and are thus very
seldom cost-effective (judged in terms of quality-adjusted life-
years gained) [9,13,71]. Randomized trials are the gold standard for
establishing the effectiveness of biomarker-guided strategies [72].
Unfortunately, there are few examples of such trials in cardiology,
particularly in the primary prevention setting [72]. Indeed, the lack
of well-designed randomized clinical trials explains the relatively
low degree of evidence (i.e., class IIa, level B) assigned to the BNP-
guided therapy in patients with chronic HF even by the most recent
guidelines [19]. However, some pivotal randomized clinical trials
on BNP-guided therapy are now in progress [27,73]. The results of
these studies will hopefully spread more light on the real usefulness
of this strategy in HF patients, pushing the adoption of BNP-guided
therapy in the management of HF patients.
4. Cardiac biomarker testing in the clinical laboratory: where
we stand
Cardiovascular biochemical biomarkers are usually measured by
means of non-competitive immunometric assay methods, using a
combination of two (or more) antisera or monoclonal antibodies
speciﬁc for separate epitopes of tested biomarkers [9,74]. However,
the set-up of a reliable and robust measurement for cardiovascular
biomarkers actually presents a very difﬁcult challenger for the ex-
perts in laboratory medicine. The desirable characteristics for an
“ideal” circulating cardiovascular biomarker, measured by laboratory
test, are reported in Table 5.
Cardiovascular biomarkers usually are peptides or proteins (includ-
ing natriuretic peptides, cardiac troponins, galectin-3 and ST2), which
are present in tissues and body ﬂuids at very low concentrations in
healthy subjects (i.e., in the range of ng/L). As a result, immunoassay
methods with very high analytical sensitivity (i.e., low detection limit,
LoD, of about 1 pg/tube or even lower) are necessary to measure with
an acceptable analytical imprecision the circulating levels of some car-
diac biomarkers (such as troponins and natriuretic peptides) in healthy
subjects, especially in pediatric age [28,29,75–78].
Furthermore, some peptide biomarkers (such as BNP) usually share
a family of related peptides in vivo and in vitro [21,79–81], while some
protein biomarkers (such as troponins) exhibit considerable chemical
and structural heterogeneity in blood of both healthy subjects of HF pa-
tients [82–84]. These heterogeneous peptides and proteins can differ-
ently cross-react with the antibodies used in immunoassay systems,
affecting the accuracy of the measurement. As a result, it is not surpris-
ing that there are large systematic differences between the circulating
Table 4
Pathophysiological and methodological characteristics of biomarkers, which are currently available and recommended by international guidelines [19].
Biomarker type Pathophysiological relevance in HF Clinical relevance in HF
(Level of evidence)
Analytical methods
ANP and BNP and their related peptides Cardiac endocrine response to changes in
hemodynamics, and to neuro-hormonal and
immune systems disturbances
Diagnosis of exclusion of HF (IA)
Prognosis of HF (IA)
Risk stratiﬁcation (IA)
Follow-up of HF patients (IIA)
Several validated immunoassay methods
using automated platforms
Cardiac troponins I and T Speciﬁc marker of injury and damage
of cardiomyocytes
Additive risk stratiﬁcation (IA) Several validated immunoassay methods
using automated platforms
Galectin−3 Noncardiac speciﬁc biomarker related
to myocardial remodeling and ﬁbrosis
Additive risk stratiﬁcation (IIB) Some immunoassay methods using automated
platforms
sST2 Noncardiac speciﬁc biomarker related
to myocardial remodeling and ﬁbrosis
Additive risk stratiﬁcation (IIB) ELISA method
Table 5
Desirable features of an ideal circulating cardiovascular biomarker measured by a
laboratory test.
− Laboratory test acceptable to patient
− Stability in vivo and in vitro of the biomarker
− Adequate analytical sensitivity (functional sensitivity) of laboratory test
− Good degree in reproducibility and accuracy of laboratory
− Easy to perform
− Complete automation of assay
− International standardization of the laboratory test
− Low cost
− Low biological variation of the biomarker
− Cardiac speciﬁcity
− Circulating levels of biomarker closely related to the pathophysiological mecha-
nisms of cardiac disease
− Circulating levels of the biomarker closely related to the therapeutic interventions
− Reference range and cut off values tested for gender, age, and ethnicity
dependence
− Diagnostic and prognostic accuracy tested by randomized clinical trials
− Cost–beneﬁt ratio favorable tested by randomized clinical trials
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levels of biomarkers measured by immunoassay methods for both cTnI
[83–85] and BNP [79,86–91].
For example, Wu et al. [92] showed since 1998 that commercial
immunoassays generated different results for a given protein con-
centration due to multiple complex forms of cTnI. According to
Apple [93], these data actually demonstrated that it was not possible
to compare absolute concentrations obtained with assays from dif-
ferent manufacturers. Commercially available cTnI assays use vari-
ous standard materials and antibodies with different epitope
speciﬁcities [83–85]. Hence, troponin I assays may yield results that
are unique to a certain method or instrument to the point that values
for a same patient sample may differ depending on the assay and
platform used [84,93]. Due to the heterogeneity between cTnI
methods and without an adequate standardization, reference values
and decision limits should be determined separately for each meth-
od and not be extrapolated from other assays. In terms of clinical
practice, this situation is obviously confusing, especially when pa-
tients are referred to different laboratories that use different cTnI
methods. Starting 2001 a study group began on the behalf of some
international organizations (such as AACC and IFCC) a process for
standardization of cTnI immunoassay methods in order to establish
a reference measurement procedure and materials [84,95].
5. Standardization or harmonization
Standardization of peptide and protein immunoassays, such as cTnI
methods, is a very complicated task [95]. A complete standardization
approach needs an accepted reference measurement procedures
(RPM) and reference materials for the TnI, which however at present
are still not available. Indeed, the term standardization can be used
only when comparable results among measurement procedures are
based on calibration traceability to SI unit using a RMP [83,84,94–96].
After over 10 years of efforts, some Authors think that cTnI assays is
unlikely to become standardized [93]. FredApple suggests laboratorians
and clinicians not get “bogged down” with cTnI standardization, en-
couraging to aim efforts toward developing a clear understanding of
the clinical and analytical evidence for cTnI immunassays and “to be
happy” that the technological improvements that have led to the
precise detection of low cTnI concentrations also will lead to better
patient care [93].
Although we completely agree with Apple that the standardization
of some critical immunoassay methods truly appears to be a “mission
impossible” [97], we do however believe that achieving better har-
monization (i.e., a reduction of heterogeneity) among the results
provided by different methods is possible. In particular, we hypothesize
that a better understanding of biochemical characteristics and the path-
ophysiological role of a candidate biomarker may promote a harmoni-
zation process indicating to manufacturers and laboratorians speciﬁc
targets (i.e., epitopes) for the set-up of more accurate immunoassay
methods. A good example for a possible harmonization process is repre-
sented by immunoassay methods for cardiac B-type-related natriuretic
peptide system.
6. The B-type cardiac natriuretic peptide system
The human BNP gene encodes for a pre-proBNP molecule of 134
amino acid residue, including a signal peptide of 26 amino acids. BNP
is cleaved out of a prohormone molecule of 108 amino acids, the
proBNP1–108 (proBNP). According to the “classical” scenario of BNP pro-
duction and secretion from cardiomyocytes, before being secreted from
cardiomyocytes into the bloodstream, proBNP is split by some proteo-
lytic enzymes (such as corin and/or furin) into two peptides: the biolog-
ically inactive NH2-terminal peptide fragment proBNP1–76 (NT-
proBNP), and the COOH-terminal peptide fragment proBNP77–108 [21]
(Fig. 1). The latter is a peptide of 32 amino acids (BNP1–32) and is usually
indicated as BNP. This is the active hormone, that is the only able to bind
to the speciﬁc natriuretic peptide receptors (named NPR-A, B, C, respec-
tively) [21].
Some recent studies open a new andmore complex scenario regard-
ing the pathophysiological and clinical relevance of circulating B-type
natriuretic peptides [22]. In addition to the peptide hormone BNP and
the inactive peptide NT-proBNP, a huge numbers of circulating
proBNP-derived fragments can be identiﬁed by chromatographic proce-
dures in human plasma, including the intact and glycosylated forms of
the precursor proBNP [98–116] (Fig. 1). Several studies have also dem-
onstrated that intact or glycosylated forms of proBNP constitute a signif-
icant portion of immunoreactive B-type-related peptides circulating in
plasma of patients with heart failure [98–116]. According to these ﬁnd-
ings, it is theoretically conceivable that the active hormone (i.e., BNP)
may be produced even in vivo from the circulating intact precursor
proBNP through enzymatic cleavage by some plasma proteases (such
as corin) [117–119]. Indeed, a recent study using an in vivo rat model
demonstrated that processing of human proBNP to active BNP can actu-
ally occur in the circulation [120]. The peripheral processing of circulat-
ing proBNP could likely be submitted to regulatory mechanisms, which
might be impaired in patients with heart failure, opening new perspec-
tives in the treatment of heart failure [80,121]. Indeed, a novel pharma-
cological target may be the pharmacodynamic action of drugs inducing
and/or modulating the maturation of the prohormone into active hor-
mone (i.e., BNP) [122].
From a methodological and analytical points of view, the large het-
erogeneity of B-type natriuretic peptides circulating in human blood
seems to explain the systematic differences among the results provided
by immunoassay methods considered speciﬁc to the peptide hormone
BNP [87,90,91,123,124]. In particular, a recent study, using standard
protocols and quality control materials, demonstrated that the IRMA
method (by Shionogi's Diagnostic Division, Japan), the ADVIA method
for the Centaur platform (by Siemens Health Care Diagnostics) and ST
AIA-PACK method for the AIA platform (by TOSOH Corporation,
Tokyo, Japan) measured greatly lower (up to the half) BNP values in
comparisonwith other immunoassays, such as the POCT Triagemethod
(by Alere Diagnostics), the BNP Triage Biosite for Access andUniCell DxI
platforms (by Beckman Coulter Diagnostics), the MEIA method for the
AxSYM platform and the chemiluminescent microparticle immunoas-
say for ARCHITECT platform (both by Abbotts Diagnostics) [124]. It is in-
teresting to note that the IRMAmethod by Shionogi, the ADVIAmethod
for Centaur platform, the ST AIA-PACK method (personal communica-
tions fromTOSOHEUROPEN.V., Tessenderlo, Belgium) use the same an-
tibodies and standard materials supplied by Shionogi's Diagnostic
Division [18].
According to the study by Luckenbill et al. [79], a great part of these
systematic differences between the different BNP immunoassay sys-
tems should be due to the cross-reaction with the glycosylated or not
glycosylated proBNP. Liang et al. [98] demonstrated that proBNP consti-
tutes a substantial portion of immunoreactive BNP measured in plasma
of HF patients.More recently, Macheret et al. [108], in study using a spe-
ciﬁc immunoassay method for proBNP [101], demonstrated that this
precursor peptide of BNP was detectable in all subjects studied, and its
levels were dependent of gender, age, heart rate, and body mass
index. Furthermore, these Authors found that the degree of clinical sen-
sitivity and speciﬁcity of proBNP assay for the detection of left ventricu-
lar dysfunction was comparable to two commercial assays for BNP and
NT-proBNP [108]. The results of this study [108] conﬁrm previous re-
ports [101–107] suggesting that the intact precursor of biologically ac-
tive BNP (i.e., the proBNP) circulates in plasma of both healthy
subjects and HF patients.
7. What B-type-related peptide should we measure and why?
According to this new scenario regarding the circulating levels of B-
type cardiac natriuretic peptides, there are at least 3 different peptides
that could be measured in human plasma samples: the active peptide
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hormone, BNP, the inactive N-terminal fragment, NT-proBNP, or the
pro-hormone peptide, proBNP [21,121]. These 3 peptides have different
biochemical characteristics and pathophysiological relevance (Table 6).
From an analytical point of view, the inactive peptide NT-proBNP
and proBNP, are more stable in vivo and in vitro, with a longer plasma
half-life and a lower intra-individual biological variation, than active
peptide BNP (Table 4) [18,21,81]. From a pathophysiological point of
view, several studies indicate that the inactive peptides, especially
proBNP, show an incremental increase of their circulating levels re-
lated to progression of HF greater than the active peptide hormone
BNP [102,103,110,115,125]. In particular, two studies [115,125],
which identiﬁed and quantiﬁed the individual cardiac natriuretic
peptides by means of mass spectrometry, reported that the real
levels of the peptide hormone BNP1–32 in patients with severe HF are
much lower than the BNP concentrations measured by commercially
available immunoassay methods. Furthermore, results of another
study using mass spectrometry determination actually provide speciﬁc
evidence for the absence (i.e., concentration below the analytical sensi-
tivity of the measurement) of circulating active peptide BNP1–32 in
advanced-stage HF patients [126].
According to the analytical characteristics and clinical results
discussed above, we would assume that the inactive peptide NT-
proBNP and proBNP would be a better biomarker for the progression
of HF than the active hormone BNP. However, at present, all the com-
mercially available immunoassay methods considered speciﬁc to ac-
tive peptide BNP signiﬁcantly cross-react with proBNP [79]. In
agreement with these data [79], a recent study [127] has found a
good correlation between the BNP and proBNP values measured
with commercially available immunoassay methods considered spe-
ciﬁc for these two peptides in patients with severe HF. Moreover, all
the international guidelines state that the commercially available
BNP and NT-proBNP immunoassays usually give clinically compara-
ble results when used for diagnosis, prognosis and follow-up of HF
patients [18,21,80,88,89,128].
At present, we must realize that the commercially available im-
munoassay methods considered speciﬁc for the active form of B-
type cardiac natriuretic peptides present an obvious paradox. From
a pathophysiological point of view, it would be better to measure
the active peptide BNP (instead of inactive peptide NT-proBNP and
proBNP) when we are interested in evaluating the “true biologically ac-
tive status” of the cardiac endocrine function [21,22]. However, to date,
none of the commercially available methods is able to provide such in-
formation, accurately, as these methods are greatly affected by inactive
peptides the concentrations of which are higher than active hormone in
the blood samples of HF patients. In other words, at present time, all the
commercially available immunoassay methods for BNP assay are not
completely speciﬁc for the active form of the peptide.
In conclusion, BNP immunoassay methods show large systematic
differences due to the interferences of some inactive peptides, especially
the glycosylated and non-glycosylated forms of the precursor peptide,
proBNP. The setup of more speciﬁc methods for the active peptide
BNP1–32 could reduce these systematic differences resulting a better
harmonization among results.
As a future perspective, a more accurate estimation of both
production/secretion of B-type related peptides from cardiomyocytes
and overall activity of the cardiac endocrine function could be achieved
by the testing plasma samples using simultaneously two methods:
one speciﬁc for the intact precursor proBNP1–108, and the other for
active peptide BNP1–32 [80,121]. Information obtained by the con-
temporaneous measurement of proBNP and BNP with speciﬁc assays
may likely extend our present understanding of pathophysiological
mechanisms linking together disease progression and cardiac endo-
crine dysfunction [80]. However, the clinical usefulness of these new
andmore speciﬁc methods will have to be accurately evaluated by ran-
domized clinical trials in comparison with NT-proBNP and proBNP
methods according to the evidence-based medicine principles [69–72].
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